Biophan Announces Availability of New 50% Smaller Model of MRI-Safe Ceramic SQUIGGLE--R-- Motor for Medical Uses; New Model Offers Increases in Power Efficiency and Precision for Uses in Drug-Delivery Systems and Other Medical Applications.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced the development of a new, ultra-small model of the implantable and wearable, highly precise ceramic SQUIGGLE motor that's half the size of previous models, with significant improvements in precision and electrical efficiency compared to electromagnetic motors.

Biophan holds the exclusive worldwide distribution rights to all medical applications of the SQUIGGLE motor, produced by New Scale Technologies. SQUIGGLE linear motors are five times more efficient and ten times more precise compared to electromagnetic motors. Biophan has been working with New Scale to develop medical applications for the proprietary motor for the $40 billion-plus market for drug delivery products.

"The SQUIGGLE motor's unique features and capabilities offer a number of important advantages as a pump to drive drug delivery systems, catheters, and other potential medical applications that require the highest levels of precision and dependability," said Michael Weiner, CEO of Biophan. "Additionally, because the SQUIGGLE is made from non-magnetic ceramic materials, it is compatible with Magnetic Resonance Imaging (MRI) environments. That means that patients who receive either the implanted or wearable SQUIGGLE-based drug delivery systems can be effectively imaged by MRI systems, allowing physicians and patients to receive the many important benefits of MRI imaging."

SQUIGGLE motors use only four parts--about 90% fewer parts than most gear-based and other medical device motors. Because they require no gear reduction, a significant source of failure and malfunction is eliminated, increasing the SQUIGGLE's dependability, about the size of a dime (see photo at http://www.biophan.com/NewScale.jpg). The new SQUIGGLE SQ-306 model is 10 mm in length and 4 mm in diameter, and achieves precision levels in the nanometer-range. The motor's improved power efficiency leads to longer battery life--a critical factor for implanted medical devices where replacements require surgical procedures. The motor's mechanical design is simple and inherently inexpensive to manufacture in high quantities, having only four parts, compared with as many as 100 parts for other biomedical motor technologies.

"At Biophan we are very pleased with the progress of New Scale, both as the exclusive distributor in the medical market, and as a minority equity owner in New Scale. New Scale has sales approaching $1 million in the market for cryogenic motors, and has an enormous potential in the emerging market for optical zoom in future cell phones," stated Mr. Weiner. "Their robust R&D and expanding patent portfolio comes at virtually no cost to us, but adds enormous value to our company. There is also an opportunity for Biophan to supply MRI safe motors that have the ability to function in cryogenic environments."

About New Scale Technologies

New Scale Technologies, Inc. makes miniature motors and precision positioning systems that are cost effective, powerful, and efficient for emerging applications in nanotechnology, microelectronics, optics, lasers, biotechnology, medical devices, aerospace and defense, fluid control, and office/consumer products. The company is privately held, located in Victor, NY and was founded in 2002 by David Henderson. The New Scale team has more than 100 years of combined experience with precision positioning and piezoelectric ceramic motors including their technologies, markets, applications, and customers. For more information, please visit www.newscaletech.com.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.